Radiodermatitis Market Report - Pipeline Review, H2 2017 - Research and Markets

DUBLIN--()--The "Radiodermatitis - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.

Radiodermatitis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Radiodermatitis (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Radiodermatitis (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Radiodermatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 1 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Radiodermatitis (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Radiodermatitis - Overview
  3. Radiodermatitis - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Pipeline by Universities/Institutes
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Radiodermatitis - Therapeutics Assessment
  10. Assessment by Target
  11. Assessment by Mechanism of Action
  12. Assessment by Route of Administration
  13. Assessment by Molecule Type
  14. Radiodermatitis - Companies Involved in Therapeutics Development
  • Daiichi Sankyo Co Ltd
  • FirstString Research Inc
  • Foresee Pharmaceuticals LLC
  • SK Chemicals Co Ltd
  • viDA Therapeutics Inc

For more information about this report visit https://www.researchandmarkets.com/research/w2kt83/radiodermatitis?w=4

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Dermatological Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Dermatological Drugs